Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more…
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in…
Cancer patients with healthier thymus glands show dramatically better responses to immunotherapy, cutting progression risks by roughly one-third and death risks by nearly half compared…
Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s…
LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity…
Artificial intelligence has moved from a background tool into a visible presence in American political advertising and its arrival is…
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer…
Men make up just 5% of people getting genetic tests for inherited cancer risks despite dying from cancer at higher rates than…
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE…
Researchers have found that people under 50 who develop colorectal cancer have unusually rigid colon tissue that helps tumors grow, offering the first clear…